My Bibliography

select

Calbert ML, Chandramouly G, Adams CM, Saez-Ayala M, Kent T, Tyagi M, Ayyadevara VSSA, Wang Y, Krais JJ, Gordon J, Atkins J, Toma MM, Betzi S, Boghossian AS, Rees MG, Ronan MM, Roth JA, Goldman AR, Gorman N, Mitra R, Childers WE, Graña X, Skorski T, Johnson N, Hurtz C, Morelli X, Eischen CM, Pomerantz RT. 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Mol Cancer Ther. 2023 Dec 8;. doi: 10.1158/1535-7163.MCT-23-0487. [Epub ahead of print] PubMed PMID: 38064712.

select

Sit YT, Takasaki K, An HH, Xiao Y, Hurtz C, Gearhart PA, Zhang Z, Gadue P, French DL, Chou ST. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis. JCI Insight. 2023 Oct 31;8(23). doi: 10.1172/jci.insight.172851. PubMed PMID: 37906251; PubMed Central PMCID: PMC10895998.

select

Alzobi M, Hurtz C, Mehta H, Thomas S, Corey SJ. B-cell lymphoblastic leukemia in an adolescent with Dravet syndrome. Pediatr Blood Cancer. 2023 Aug;70(8):e30340. doi: 10.1002/pbc.30340. Epub 2023 Apr 19. PubMed PMID: 37073671.

select

Hurtz C, Ayyadevara AV, Wertheim G, Chukinas JA, Loftus JP, Lee SJ, Kumar A, Bhansali RS, Swaminathan S, Geng H, Milne T, Hua X, Bernt KM, Besson T, Shi J, Crispino JD, Carroll M, Tasian S. Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition. [preprint]. 2022 October. Available from: https://www.biorxiv.org/content/10.1101/2022.10.02.510349v1.

select

Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda L, McDonald T, Lacayo NJ, Sakamoto KM, Carroll M, Tasian SK, Marcucci G, Yu J, Caligiuri MA, Maecker HT, Swaminathan S. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021 Oct 21;138(16):1465-1480. doi: 10.1182/blood.2020009871. PubMed PMID: 34077953; PubMed Central PMCID: PMC8532198.

select

Hurtz C, Wertheim GB, Loftus JP, Blumenthal D, Lehman A, Li Y, Bagashev A, Manning B, Cummins KD, Burkhardt JK, Perl AE, Carroll M, Tasian SK. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. J Clin Invest. 2020 Jul 1;130(7):3637-3653. doi: 10.1172/JCI134424. PubMed PMID: 32191635; PubMed Central PMCID: PMC7324172.

select

Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. Genes Dev. 2019 Sep 1;33(17-18):1265-1279. doi: 10.1101/gad.327593.119. Epub 2019 Aug 8. PubMed PMID: 31395741; PubMed Central PMCID: PMC6719625.

select

Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D. Extrafollicular CD4(+) T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun. 2017 Oct 17;8(1):978. doi: 10.1038/s41467-017-00880-2. PubMed PMID: 29042531; PubMed Central PMCID: PMC5645449.

select

Tasian SK, Hurtz C, Wertheim GB, Bailey NG, Lim MS, Harvey RC, Chen IM, Willman CL, Astles R, Zebrowski A, Reshmi SC, Li MM, Frey NV, Luger SM, Carroll M, Perl AE. High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL. Leukemia. 2017 Apr;31(4):981-984. doi: 10.1038/leu.2016.375. Epub 2016 Dec 9. PubMed PMID: 27932787; PubMed Central PMCID: PMC5382063.

select

Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA. Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017 Mar 2;129(9):1155-1165. doi: 10.1182/blood-2016-06-722900. Epub 2016 Dec 28. PubMed PMID: 28031181; PubMed Central PMCID: PMC5374732.

select

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13. PubMed PMID: 28192788; PubMed Central PMCID: PMC5621518.

select

Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol. 2017 Feb 15;13(2):914. doi: 10.15252/msb.20167159. PubMed PMID: 28202506; PubMed Central PMCID: PMC5327725.

select

Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9. Epub 2016 Feb 5. PubMed PMID: 26847027; PubMed Central PMCID: PMC5459356.

select

Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):114-28. doi: 10.1016/j.ccell.2015.05.008. Epub 2015 Jun 11. PubMed PMID: 26073130; PubMed Central PMCID: PMC4565502.

select

Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 9;27(3):409-25. doi: 10.1016/j.ccell.2015.02.003. PubMed PMID: 25759025; PubMed Central PMCID: PMC4618684.

select

Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014 May 27;111(21):E2219-28. doi: 10.1073/pnas.1400958111. Epub 2014 May 12. PubMed PMID: 24821775; PubMed Central PMCID: PMC4040579.

select

Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013 Aug;19(8):1014-22. doi: 10.1038/nm.3247. Epub 2013 Jul 14. PubMed PMID: 23852341; PubMed Central PMCID: PMC3954721.

select

Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. J Exp Med. 2013 Apr 8;210(4):805-19. doi: 10.1084/jem.20121482. Epub 2013 Mar 11. PubMed PMID: 23478187; PubMed Central PMCID: PMC3620349.

select

Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2013 Jan 3;121(1):148-55. doi: 10.1182/blood-2012-05-428938. Epub 2012 Nov 14. PubMed PMID: 23152540; PubMed Central PMCID: PMC3538327.

select

Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012 Nov;2(11):1004-23. doi: 10.1158/2159-8290.CD-12-0208. Epub 2012 Oct 29. PubMed PMID: 23107779; PubMed Central PMCID: PMC3516186.

select

Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24;208(11):2163-74. doi: 10.1084/jem.20110304. Epub 2011 Sep 12. PubMed PMID: 21911423; PubMed Central PMCID: PMC3201200.

select

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 May 19;473(7347):384-8. doi: 10.1038/nature09883. PubMed PMID: 21593872; PubMed Central PMCID: PMC3597744.

select

Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010 Jun 7;207(6):1209-21. doi: 10.1084/jem.20091299. Epub 2010 May 24. PubMed PMID: 20498019; PubMed Central PMCID: PMC2882829.